Date: 2015-03-05
Type of information: Series A financing round
Company: Genenta Science (Italy)
Investors: Banca Esperia (Italy) Mediolanum (Italy) private investors
Amount: € 10 million
Funding type: series A financing round
Planned used: Genenta Science is an italian biotech start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini, Director of the San Raffaele-Telethon Institute for Gene Therapy, TIGET and of the Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Hospital; and Bernhard Gentner, Haematologist and Physician Scientist at the San Raffaele Hospital and TIGET. The company has developed a gene transfer strategy into autologous hematopoietic stem cells (HSCs) to target interferon-? expression to tumor-infiltrating monocytes/macrophages. A lentiviral vector delivers the gene into the HSCs. Geneta's therapy, using a combination of transcriptional and microRNA-mediated control, tumor-infiltrating monocytes/macrophages allows to selectively express interferon limited to the tumor area, thus reducing its toxicity. Based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, TIE2-expressing monocytes with proangiogenic activity, are "armed" with a specific drug. This series A financing round allows Genenta Science to complete pre-clinical studies and to advance in the preparation of the clinical phase for its therapeutic protocols to treat tumors.
Others: * On March 5, 2015, Genenta Science announced that the company has banked an overall € 10 million ($ 11.0 million) Series A financing round. The funding campaign was supported by Banca Esperia, the Private Bank of Mediobanca and * On January 23, 2015, Genenta Science announced that the company has raised € 6.2 million. The new start-up aims to close the Series A round at € 10 million in the next few weeks.
Mediolanum. The Series A round was led by private investors: entrepreneurs, managers, HNWI, family offices.
Therapeutic area: Cancer - Oncology - Rare diseases
